Demographic characteristics of the patients (n=47)
| Variable | Value |
| Age, years, mean (SD) | 48.3 (12.7) |
| Female sex, n(%) | 28 (59.6) |
| Body mass index, kg/m2, mean (SD) | 27.1 (4.8) |
| Disease duration, years, median (IQR) | 8.3 (4.3) |
| Education duration, years, mean (SD) | 13.6 (3.6) |
| Documented axial disease, n (%) n=42 | 15 (35.7) |
| bDMARD | |
| Adalimumab, n (%) | 7 (14.9) |
| Certolizumab, n (%) | 8 (17) |
| Etanercept, n (%) | 15 (31.9) |
| Golimumab, n (%) | 16 (34) |
| Ustekinumab, n (%) | 1 (2.1) |
| Concomitant medication | |
| Prednisolone, n (%) | 5 (10.6) |
| Methotrexate, n (%) | 22 (46.8) |
| Sulphasalazine, n (%) | 1 (2.1) |
| Cyclosporine, n (%) | 1 (2.1) |
bDMARD, biological disease-modifying antirheumatic drug.